Oncology
HER2+ Breast Cancer
Receptor amplification, trastuzumab antibodies, and the dawn of targeted therapy
HER2-positive breast cancer amplifies the HER2 oncogene 6-100x, driving aggressive growth. Trastuzumab (Herceptin) binds HER2, blocks dimerization, and recruits NK cells. Adjuvant trastuzumab improves survival by 30%+.
- HER2+ prevalence~15-20% of invasive breast cancers
- GeneERBB2 on chromosome 17q12
- Amplification6-100+ extra copies; ~10⁶ receptors/cell
- First-line antibodyTrastuzumab (Herceptin) — approved 1998
- Adjuvant impact~30%+ overall survival improvement
- Diagnostic testsIHC 3+ or ISH ratio ≥2.0
Interactive visualization
Press play, or step through manually. Watch a HER2-overexpressing cell signal, then see trastuzumab antibodies bind, block dimerization, and recruit NK cells.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
How it works
HER2 (human epidermal growth factor receptor 2; gene name ERBB2) is a transmembrane receptor tyrosine kinase of the EGFR family. Unlike its siblings, HER2 has no known soluble ligand — it sits open on the cell surface, ready to dimerize. Normally a single allele copy yields about 20,000 receptors per cell. In about 15-20% of invasive breast cancers, the ERBB2 gene is amplified six to a hundred times over, plastering the cell surface with up to a million HER2 molecules. They homodimerize constitutively and heterodimerize preferentially with HER3 — the most potent oncogenic pair in this family.
Dimerization activates the intracellular kinase domain, which trans-phosphorylates the partner. Phosphotyrosines recruit adapters that turn on two key downstream pathways: PI3K → AKT → mTOR (survival, growth, protein synthesis) and RAS → RAF → MEK → ERK (proliferation, motility). The tumor grows fast, metastasizes early to lung, liver, brain, and bone, and resists tamoxifen even when estrogen receptor is co-expressed.
Trastuzumab is a humanized IgG1 monoclonal antibody against the extracellular subdomain IV of HER2. It works through at least four mechanisms: blocking ligand-independent dimer signaling, inducing receptor internalization and degradation, inhibiting cleavage of the soluble HER2 ectodomain, and recruiting the innate immune system via antibody-dependent cellular cytotoxicity (ADCC). Its Fc tail binds FcγRIIIa on NK cells, which release perforin and granzymes onto the tagged cancer cell. Pertuzumab is a second antibody that binds subdomain II, blocking HER2-HER3 heterodimerization. Trastuzumab plus pertuzumab is now standard in both neoadjuvant and metastatic disease — they hit different epitopes and synergize.
Worked clinical example
A 48-year-old woman finds a 2.4 cm lump in her right breast. Core biopsy: invasive ductal carcinoma, grade 3, ER 0%, PR 0%, HER2 IHC 3+ (confirmed by FISH ratio 8.4). Axillary ultrasound shows two suspicious nodes; biopsy confirms metastasis. Staging CT and bone scan are negative for distant disease — stage IIIA HER2-positive, hormone-receptor-negative breast cancer. She enters neoadjuvant therapy: 12 weeks of THP (paclitaxel + trastuzumab + pertuzumab) followed by 4 cycles of AC (doxorubicin + cyclophosphamide). At surgery, the breast and nodes show complete pathological response (ypT0 ypN0) — a strong prognostic marker in HER2-positive disease. She completes one year of adjuvant trastuzumab + pertuzumab, with serial echos showing stable LVEF. Five-year disease-free survival in this scenario (pCR HER2+) is in the 90%+ range. Had residual disease been present, she would have switched to adjuvant T-DM1 per the KATHERINE trial — which cut recurrence risk by half compared with trastuzumab alone in that setting.
The HER2 drug class — past, present, future
- Trastuzumab (1998) — the original. Adjuvant cuts recurrence ~50%, improves OS 30%+.
- Lapatinib (2007) — small-molecule HER1/HER2 tyrosine kinase inhibitor. Crosses BBB, useful for brain metastases.
- Pertuzumab (2012) — anti-dimerization antibody; combined with trastuzumab extends OS in metastatic disease (CLEOPATRA: 40.8 → 56.5 months).
- T-DM1 (ado-trastuzumab emtansine) (2013) — first ADC: trastuzumab linked to a microtubule poison. Standard for residual disease after neoadjuvant.
- Neratinib (2017) — irreversible pan-HER TKI, oral extended adjuvant.
- Tucatinib (2020) — selective HER2 TKI, excellent CNS penetration. HER2CLIMB: combined with trastuzumab + capecitabine improves OS in brain-metastatic disease.
- T-DXd (trastuzumab deruxtecan) (2022) — second-generation ADC with topoisomerase-I payload and bystander effect. DESTINY-Breast03 doubled PFS vs. T-DM1; DESTINY-Breast04 transformed HER2-low metastatic disease.
- Bispecifics and CAR-T — zanidatamab (HER2 × HER2 bispecific), HER2-targeted CAR-T in early trials; the next wave.
Common pitfalls
- Calling 2+ "positive" without ISH. IHC 2+ is equivocal — it must be confirmed by FISH or other ISH for HER2 ratio ≥2.0 before classifying as HER2-positive. Misclassification means over- or under-treatment.
- Ignoring HER2-low. Since DESTINY-Breast04, IHC 1+ or 2+/ISH-negative tumors qualify for T-DXd in the metastatic setting. The label "HER2-negative" is now obsolete — re-test or re-stain archival blocks if needed.
- Stacking trastuzumab with anthracycline. Concurrent doxorubicin and trastuzumab roughly triples heart failure risk. Sequence anthracycline first, then trastuzumab; or use anthracycline-sparing TCH.
- Skipping serial echocardiograms. Trastuzumab cardiotoxicity is largely reversible if caught — but only if you monitor. Echo every 3 months on therapy.
- Missing T-DXd-induced interstitial lung disease. Up to 10% of patients on T-DXd develop ILD; ~1% fatal. New cough, dyspnea, or hypoxia warrants immediate chest CT and steroid initiation.
- Forgetting brain MRI surveillance. HER2-positive metastatic disease has high CNS tropism (30-50% develop brain metastases). Symptomatic screening — and consideration of tucatinib-based regimens at progression — matters.
| Drug | Class | Mechanism | Pivotal data |
|---|---|---|---|
| Trastuzumab | Antibody (anti-HER2 domain IV) | Blocks dimerization + ADCC via NK cells | Adjuvant: ~50% relative recurrence reduction |
| Pertuzumab | Antibody (anti-HER2 domain II) | Blocks HER2-HER3 heterodimerization | CLEOPATRA OS 40.8 → 56.5 months |
| T-DM1 | ADC (microtubule payload) | Targeted delivery of DM1 | KATHERINE: 50% reduction in recurrence (residual disease) |
| T-DXd | ADC (topo-I payload, bystander) | Targeted delivery of DXd | DESTINY-Breast03: PFS doubled vs. T-DM1 |
| Lapatinib | Small-molecule TKI | Reversible HER1/HER2 kinase block | CNS-penetrant; older oral option |
| Tucatinib | Small-molecule TKI | Selective HER2; excellent CNS penetration | HER2CLIMB: OS gain in brain-metastatic disease |
| Neratinib | Small-molecule TKI | Irreversible pan-HER | Extended adjuvant; significant diarrhea |
Frequently asked questions
What does it mean to be HER2-positive?
HER2 positivity is defined by amplification of the ERBB2 gene on chromosome 17q12 — the cancer cell carries 6 to 100+ extra gene copies, leading to overexpression of the HER2 receptor at the cell surface (often a million or more copies per cell vs. ~20,000 normal). Diagnosis combines immunohistochemistry (IHC 3+) and/or in-situ hybridization (ISH ratio ≥2.0). About 15-20% of invasive breast cancers are HER2-positive. The phenotype is more aggressive — higher grade, more visceral and CNS metastases — but also more druggable than any other breast subtype because of the cleanly amplified target.
How does trastuzumab work?
Trastuzumab (Herceptin) is a humanized IgG1 monoclonal antibody that binds the extracellular domain IV of HER2. It works through multiple mechanisms: (1) blocks ligand-independent HER2-HER2 homodimerization and downstream PI3K-AKT signaling; (2) triggers receptor internalization and degradation; (3) recruits the immune system through antibody-dependent cellular cytotoxicity (ADCC) — its Fc portion engages FcγRIIIa on NK cells, which release perforin and granzymes; (4) inhibits HER2 ectodomain shedding. Given as adjuvant therapy (typically 12 months) after chemotherapy, it cuts the risk of recurrence by about half and improves overall survival by 30%+ over chemotherapy alone.
What is an antibody-drug conjugate?
An ADC marries the targeting precision of a monoclonal antibody to a potent cytotoxic payload, joined by a chemical linker. Trastuzumab-emtansine (T-DM1) uses an uncleavable linker to a microtubule poison (DM1); trastuzumab deruxtecan (T-DXd) uses a cleavable linker to a topoisomerase-I inhibitor (DXd) with bystander activity — once released, it kills neighboring HER2-low cells too. T-DXd has rewritten the treatment of HER2-low (IHC 1+ or 2+ / ISH–) disease, in which classical trastuzumab is ineffective. ADCs deliver chemotherapy specifically to HER2-positive cells, sparing healthy tissue. Key toxicities: T-DXd causes interstitial lung disease in ~10% (vigilance required); T-DM1 causes thrombocytopenia and transaminase elevation.
What is pertuzumab?
Pertuzumab is a second anti-HER2 antibody that binds extracellular domain II of HER2 — the dimerization arm. Trastuzumab and pertuzumab bind different epitopes, so they are complementary, not redundant. Together they block both HER2-HER2 homodimerization and HER2-HER3 heterodimerization, the strongest oncogenic driver. In the CLEOPATRA trial, adding pertuzumab to trastuzumab and docetaxel improved median overall survival in metastatic HER2-positive breast cancer from 40.8 to 56.5 months — one of the largest survival gains in any breast cancer trial. The neoadjuvant THP regimen (trastuzumab + pertuzumab + paclitaxel) is now a standard for stage II-III HER2-positive disease.
What about cardiotoxicity?
Trastuzumab can reduce left ventricular ejection fraction (LVEF). The mechanism: cardiomyocytes use HER2 signaling for stress response; blocking HER2 with concurrent anthracyclines (doxorubicin, epirubicin) increases cardiotoxicity. Risk: ~3-7% develop symptomatic heart failure; up to ~20% have subclinical LVEF drop. Mitigation: baseline echocardiogram, monitoring every 3 months on therapy, hold trastuzumab if LVEF falls ≥10% from baseline AND below 50%, restart after recovery. Unlike anthracycline cardiotoxicity, trastuzumab-induced dysfunction is largely reversible. Sequencing anthracycline first, then trastuzumab, is now standard; anthracycline-sparing regimens (TCH = docetaxel + carboplatin + trastuzumab) are preferred for many.
Is HER2 only in breast cancer?
No. HER2 amplification occurs in gastric and gastroesophageal junction cancer (15-20%, indication for trastuzumab in the ToGA trial), HER2-mutated lung cancer (treated with T-DXd), HER2-positive colorectal (~3%, off-label trastuzumab + tyrosine kinase inhibitors), bladder cancer, salivary gland cancer, and some uterine serous carcinomas. The 2022 'tissue-agnostic' approval of T-DXd for HER2-expressing solid tumors marked a major shift: target-driven approval based on biomarker, not organ of origin. Testing for HER2 by IHC/ISH is now routine in many cancers beyond breast.
What is HER2-low?
HER2-low is defined as IHC 1+, or IHC 2+ with negative in-situ hybridization — formerly grouped with HER2-negative because classical trastuzumab does not help. About 60% of historically 'HER2-negative' breast cancers actually express low levels of HER2. The DESTINY-Breast04 trial showed trastuzumab deruxtecan (T-DXd) doubled progression-free survival vs. chemotherapy in HER2-low metastatic breast cancer (10.1 vs. 5.4 months) and improved overall survival (23.9 vs. 17.5 months). The result rewrote breast cancer subtype definitions — HER2-low is now an actionable category.